Background
==========

Triple-negative breast cancer (TNBC) is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER-2), and accounts for 15--20% of all breast cancers ([@bib1]). Due to this lack of the common therapeutic targets, TNBCs are associated with the worst prognosis and one of the highest risks of metastasis among all subtypes of breast cancer ([@bib2], [@bib3]).

Further, several population-based studies have shown that TNBC often presents at a younger age despite lack of ER, and older patients may have a better outcome when compared with their younger counterparts ([@bib4], [@bib5]). An epidemiology survey of basal-like breast cancer has revealed that the alterations of hormones throughout a woman's life are linked to the risk of developing TNBC ([@bib6]). Overall, while these recent studies suggest that estrogen plays a role in the management of TNBC, the mechanism of estrogen involvement remains undefined.

Although TNBCs lack classic nuclear ERs, more evidence demonstrates estrogen could influence cell proliferation and migration elicited by combining steroid hormone receptors such as G protein-coupled estrogen receptor 1 (GPER), ERβ or estrogen-related receptors ([@bib7], [@bib8], [@bib9], [@bib10]).

GPER, also known as G protein-coupled receptor 30 (GPR30), used to be considered an orphan receptor. Later, two groups independently proved that GPER binds to and is activated by estradiol, and in response, initiates intracellular signaling cascades ([@bib10], [@bib11], [@bib12]). Although controversies still exist on the specificity of the binding between GPER and estrogen, most studies currently conclude that GPER is driven by estrogen and is compatible with the pattern of ligand--receptor binding ([@bib13], [@bib14]). Our previous study showed that treatment with 17b-estradiol (E2) in MDA-MB-231 TNBC cells resulted in Ezrin-dependent cytoskeleton rearrangement, and elicited a stimulatory effect on cell migration and invasion. Importantly, we observed that Ezrin phosphorylation, cell migration and invasion activated by E2 could be significantly inhibited by silencing GPER signaling ([@bib15]), indicating that E2 induces the phosphorylation of Ezrin protein by GPER to mediate important cellular activities in TNBC cells. Moreover, the expression of GPER in TNBC is extensive and its downstream signaling pathway has been proved to be involved in proliferation, metastasis and angiogenesis in TNBC ([@bib16], [@bib17]). However, the function of GPER in TNBC remains controversial. As reported in some studies, activation of GPER may suppress the epithelial--mesenchymal transition of TNBC cells ([@bib18]).

Therefore, the current study aimed to determine GPER and Ezrin immunopositivity in a cohort of TNBC patients, to understand the characteristics and prognostic value of GPER, and the possible relationship between these two in TNBC. Furthermore, we investigated a potential association of GPER and Ezrin with the clinicopathological parameters of TNBC.

Materials and methods
=====================

Specimen characteristics and ethical approval
---------------------------------------------

FFPE tissue was derived from 249 patients diagnosed with TNBC at our institution from 1999 to 2011. The eligibility criteria were pathologically confirmed TNBC, underwent primary tumor resection after diagnosis and availability of follow-up data. For each case, detailed clinicopathological characteristics including age, menopausal status, tumor size, nuclear grade, lymph node metastasis (LNM) and AJCC TNM stage were routinely abstracted from the medical record and are shown in compliance with the REMARK criteria ([@bib19]) in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. This study was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center, and all patients had provided written informed consent for their data and surgical specimens to be used for research purposes. Table 1GPER positivity in TNBC as correlated with clinicopathological factor.AllGPER-lowGPER-high*P*\*Menopause status Pre-menopause196 (78.7)140 (79.5)56 (76.7)0.619 Post-menopause53 (21.3)36 (20.5)17 (23.3)Tumor size (pT, cm) pT176 (30.5)48 (27.3)28 (38.4)0.113 pT2147 (59.0)110 (62.5)37 (50.7) pT320 (8.0)15 (8.5)5 (6.8) pT46 (2.4)2 (1.1)4 (5.5)Nuclear grade II48 (19.3)34 (19.3)14 (19.2)0.980 III201 (80.7)142 (80.7)59 (80.8)LNM^\#^ pN0133 (53.4)101 (57.4)32 (43.8)0.101 pN158 (23.3)41 (23.3)17 (23.3) pN234 (13.7)21 (11.9)13 (17.8) pN324 (9.6)13 (7.4)11 (15.1)TNM staging^\#^ I38 (15.3)27 (15.3)11 (15.1)0.021 IIa108 (43.4)80 (45.5)28 (38.4) IIb40 (16.1)33 (18.8)7 (9.6) IIIa34 (13.7)22 (12.5)12 (16.4) IIIb5 (2.0)1 (0.6)4 (5.5) IIIc24 (9.6)13 (7.4)11 (15.4)Local treatment Mastectomy84 (33.7)59 (33.5)25 (34.2)0.373 Quadrantectomy13 (5.2)7 (4.0)6 (8.2) Mastectomy + RT149 (59.8)107 (60.8)42 (57.5) Quadrantectomy + RT3 (1.2)3 (1.7)0 (0)Chemotherapy Yes179 (71.9)127 (72.2)52 (71.2)0.882 No70 (28.1)49 (27.8)21 (28.8)Death Yes64 (25.7)31 (17.6)33 (45.2)\<0.001 No185 (74.3)145 (82.4)40 (54.8)Relapse event Yes34 (13.7)14 (8.0)20 (27.4)\<0.001 No215 (86.3)162 (92.0)53 (71.6)Distant event Yes53 (21.3)18 (10.2)35 (47.9)\<0.001 No196 (78.7)158 (89.8)38 (52.1)[^2][^3] Table 2Ezrin positivity in TNBC as correlated to clinicopathological factor.AllEzrin-lowEzrin-high*P*\*Menopause status Pre-menopause196 (78.7)134 (79.3)62 (77.5)0.747 Post-menopause53 (21.3)35 (20.7)18 (22.5)Tumor size (pT, cm) pT176 (30.5)48 (28.4)28 (35.0)0.166 pT2147 (59.0)104 (61.5)43 (53.8) pT320 (8.0)15 (8.9)5 (6.3) pT46 (2.4)2 (1.2)4 (5.0)Nuclear grade II48 (19.3)37 (21.9)11 (13.8)0.128 III201 (80.7)132 (78.1)69 (27.7)LNM^\#^ pN0133 (53.4)98 (58.0)35 (43.8)0.136 pN158 (23.3)38 (22.5)20 (25.0) pN234 (13.7)20 (11.8)14 (17.5) pN324 (9.6)13 (7.7)11 (13.8)TNM staging^\#^ I38 (15.3)26 (15.4)12 (15.0)0.221 IIa108 (43.4)78 (46.2)30 (37.5) IIb40 (16.1)30 (17.8)20 (12.5) IIIa34 (13.7)20 (11.8)14 (17.5) IIIb5 (2.0)2 (1.2)3 (3.8) IIIc24 (9.6)13 (7.7)11 (13.8)Local treatment Mastectomy84 (33.7)60 (35.5)24 (30.0)0.190 Quadrantectomy13 (5.2)6 (3.6)7 (8.8) Mastectomy + RT149 (59.8)100 (59.2)49 (61.3) Quadrantectomy + RT3 (1.2)3 (1.8)0 (0)Chemotherapy Yes179 (71.9)118 (69.8)61 (76.3)0.292 No70 (28.1)51 (30.2)19 (23.8)Death Yes64 (25.7)29 (17.2)35 (43.8)\<0.001 No185 (74.3)140 (82.8)45 (56.2)Relapse event Yes34 (13.7)17 (10.1)17 (21.3)0.016 No215 (86.3)152 (89.9)63 (78.7)Distant event Yes53 (21.3)15 (8.9)38 (47.5)\<0.001 No196 (78.7)154 (91.1)42 (52.5)[^4][^5]

Immunohistochemistry
--------------------

In the histopathological reports, GPER and Ezrin were evaluated with immunohistochemistry. Formalin-fixed paraffin-embedded tumor tissues were conventionally sectioned and then deparaffinized, hydrated and endogenous peroxidase activity was blocked with 3% H~2~O~2~ for 10 min. Pressure cooker antigen retrieval was carried out in EDTA for GPER (pH = 9.0) and Ezrin (pH = 8.0) for 2 min 30 s to enhance immunoreactivity. Samples were then incubated with a GPER primary antibody (1:100 dilution, rabbit polyclonal, ab39742, Abcam) and Ezrin antibody (1:100 dilution, rabbit polyclonal, NBP2-16396, Novus, CO, USA) overnight at 4°C. After washing with phosphate-buffered saline (PBS), the slides were treated with a peroxidase anti-rabbit secondary antibody (Zhongshan Golden Bridge Biotechnology, Beijing, China) at 37.5°C for 30 min. Subsequently, DAB (Zhongshan Golden Bridge Biotechnology, Beijing, China) was used to stain the slides. Endometrial carcinoma tissue and renal cell carcinoma tissue were used as positive staining control, respectively, which has been demonstrated to express GPER and Ezrin ([@bib20], [@bib21]). Two positive control tissues exchanged the primary antibody to check for unspecific staining as the negative control (Supplementary Fig. 1, see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article).

IHC scoring
-----------

Two independent pathologists blindly scored all the specimens by consensus. The IHC staining was quantified by applying the immunoreactive score ([@bib22]), which is calculated by multiplying the staining intensity (grade as 0, negative; 1, weak; 2, moderate; and 3, strong staining) and percentage of positively stained cells (0;  \< 5%; 5--24%; 25--49%; 50--74%; 75--100%). An ROC curve of the survival result for all intensity levels was plotted to generate the optimal cut-off value of GPER and Ezrin expression (Supplementary Table 1). The immunoreactive score of IRS = 0.8 was used to distinguish between low and high expression of both GPER and Ezrin.

Statistical analyses
--------------------

Chi-squared test or Fisher's exact test was used to analyze the association of GPER and Ezrin status with clinicopathological variables. End points including local relapse, distant metastasis, death and any progression were used to calculate the LRFS (local relapse-free survival), DDFS (distant disease-free survival), OS (overall survival) and PFS (progression-free survival). Kaplan--Meier survival analysis and log-rank test were utilized to compare the survival outcome. Multivariate analysis using a Cox proportional hazard model was performed based on variables with a *P* value of \<0.05 from the logistic regression. All significance level of statistics was set at 0.05 except multivariate model which was set at 0.01.

Results
=======

Patient characteristics
-----------------------

During the period of study, 249 cases of primitive invasive breast cancer were diagnosed as TNBC for which the clinicopathological characteristics were available. As shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, all patients in our study (249/249, 100.0%) were assigned as intermediate (G2) or high grade (G3). For TNM grouping, a total of 249 cases were enrolled with 15.2% (38/249) at stage I, 59.5% (148/249) at stage II and 25.3% (63/249) at stage III. Overall median age at diagnosis was 47 years (range, 23--80 years). More than two-thirds (*n* = 196, 78.7%) of patients were in pre-menopause.

Immunoreactivity of GPER and Ezrin in TNBC tissue
-------------------------------------------------

Examples of negative (0), weak (1), moderate (2) and strong (3) GPER and Ezrin staining intensity are shown in [Figs 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. GPER and Ezrin staining were detected in the large majority (177/249, 71.1%; 185/249, 74.3%) of TNBC tissue samples. In general, the expression level of GPER and Ezrin were found to be different in cancer nests and adjacent tissues in positive specimens. According to the cut-off IHC score, low and high GPER expression levels were found in 70.7% (176/249) and 29.3% (73/249) of patients, respectively, and 32.1% (80/249) of specimens had high expression of Ezrin ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Among them, 55.4% (138/249) of cases were GPER/Ezrin-low expression and 16.9% (42/249) were GPER/Ezrin-high. Overall, GPER and Ezrin were detected in both cytoplasm and cell membranes of all positively stained sections. The expression level of GPER and Ezrin were found to be different in cancer nests and adjacent tissues (data not shown).Figure 1GPER expression in TNBC tissue. Representative IHC figures of GPER grade: (A) negative (0), (B) weak (1), (C) moderate (2) and (D) strong staining (3). Scale bar equals 100 μm. Figure 2Ezrin expression in TNBC tissue. Representative IHC figures of Ezrin grade: (A) negative (0), (B) weak (1), (C) moderate (2) and (D) strong staining (3). Scale bar equals 100 μm.

The association of GPER and Ezrin expression with clinicopathological factors
-----------------------------------------------------------------------------

The association of GPER and Ezrin expression with some clinicopathologic variables was assessed. As shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, high GPER expression was significantly associated with high TNM staging (I, 15.1 vs 15.3%; IIa, 38.4 vs 45.5%; IIb, 9.6 vs 18.8%; IIIa, 16.4 vs 12.5%; IIIb, 5.5 vs 0.6%; IIIc, 15.4 vs 7.4%; *P* = 0.021), more death (45.2 vs 17.6%; *P* \< 0.001), relapse (27.4 vs 8.0%; *P* \< 0.001) and distant events (47.9 vs 10.2%; *P* \< 0.001). Similarly, a higher ratio of death (45.3 vs 17.2%; *P* \< 0.001), local relapse (21.3 vs 10.1%; *P* = 0.016) and distant metastasis (47.5 vs 8.9%; *P* \< 0.001) was observed in high Ezrin patients, but not in other variables.

The relationship between GPER, Ezrin and long-term survival outcome
-------------------------------------------------------------------

Kaplan--Meier analysis showed that in all 249 cases, patients with high GPER expression in tumors had a significantly lower OS (*P* \< 0.001), PFS (*P* \< 0.001), LRFS (*P* \< 0.001) and DDFS (*P* \< 0.001) rate than those with low GPER expression ([Fig. 3](#fig3){ref-type="fig"}). However, further analysis of patients stratified by menopause status demonstrated that, in the pre-menopause subgroup, the patients with high GPER expression had a significantly lower OS (*P* \< 0.001), PFS (*P* \< 0.001), LRFS (*P* \< 0.001) and DDFS (*P* \< 0.001) rate than those with low GPER expression ([Fig. 4](#fig4){ref-type="fig"}), but no statistically significant difference was observed in terms of OS (*P* = 0.8617), PFS (*P* = 0.1905), LRFS (*P* = 0.4378) and DDFS (*P* = 0.2538) rate between the patients with high and low GPER expression in the post-menopause group ([Fig. 5](#fig5){ref-type="fig"}). There is no interaction effect of survival outcome between GPER level and menopause status (*P* = 0.716; Supplementary Fig. 2).Figure 3Kaplan--Meier curves comparing survival outcome of TNBC patients with high and low GPER expression. Patients with high GPER expression had a significantly lower OS (A), PFS (B), LRFS (C) and DDFS (D) rate than those with low GPER expression. Figure 4Kaplan--Meier curves comparing survival outcome of pre-menopause TNBC patients with high and low GPER expression. In the pre-menopause subgroup, patients with high GPER expression had a significantly lower OS (A), PFS (B), LRFS (C) and DDFS (D) rate than those with low GPER expression. Figure 5Kaplan--Meier curves comparing survival outcome of post-menopause TNBC patients with high and low GPER expression. In the post-menopause subgroup, there were no significant differences in OS (A), PFS (B), LRFS (C) and DDFS (D) between high and low GPER expression patients.

Spearman correlation showed that there is positive relationship between the full range expression of GPER and Ezrin in our TNBC samples ([Table 3](#tbl3){ref-type="table"}, *R* = 0.508, *P* \< 0.001). An effect on survival prognosis by Ezrin, similar to the GPER effect, was observed. The high expression of Ezrin also could significantly decrease the patients' OS (*P* \< 0.001), PFS (*P* \< 0.001), LRFS (*P* = 0.0122) and DDFS (*P* \< 0.001) rate ([Fig. 6](#fig6){ref-type="fig"}). The statistical differences in the prognostic value of Ezrin disappeared in post-menopause patients ([Figs 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}).Figure 6Kaplan--Meier curves comparing survival outcome of TNBC patients with high and low Ezrin expression. Patients with high Ezrin expression had a significantly lower OS (A), PFS (B), LRFS (C) and DDFS (D) rate than those with low Ezrin expression. Figure 7Kaplan--Meier curves comparing survival outcome of pre-menopause TNBC patients with high and low Ezrin expression. In the pre-menopause subgroup, patients with high Ezrin expression had a significantly lower OS (A), PFS (B), LRFS (C) and DDFS (D) rate than those with low Ezrin expression. Figure 8Kaplan--Meier curves comparing survival outcome of post-menopause TNBC patients with high and low Ezrin expression. In the post-menopause subgroup, there were no significant differences in OS (A), PFS (B), LRFS (C) and DDFS (D) between high and low Ezrin expression patients. Table 3Positive relationship between expression of GPER and Ezrin.EzrinGPER-lowGPER-high*R*\**P*Low169 (67.9)138 (78.4)31 (42.5)0.508\<0.001High80 (32.1)38 (21.6)42 (57.5)[^6]

By further subgrouping, we found that high co-expression of GPER/Ezrin was significantly linked to the worst OS (*P* \< 0.001), PFS (*P* = 0.269), LRFS (*P* = 0.001) and DDFS (*P* \< 0.001) of patients compared to the low co-expression of GPER/Ezrin group ([Fig. 9](#fig9){ref-type="fig"}).Figure 9Kaplan--Meier curves comparing survival outcome of TNBC patients with co-expression of GPER/Ezrin. Patients with high co-expression of GPER/Ezrin had significantly lower OS (A), PFS (B), LRFS (C) and DDFS (D) rates than those with low co-expression of GPER/Ezrin group.

We then used logistic regression and Cox regression to identify the prognostic value of GPER, Ezrin expression and other clinicopathologic variables in univariate and multivariate models. As presented in [Table 4](#tbl4){ref-type="table"}, which was adjusted for those risk factors, the multivariate analysis revealed that high GPER still independently predicted poor PFS (HR = 0.393; 95% CI 0.246--0.629; *P* \< 0.001), LRFS (HR = 0.329; 95% CI 0.153--0.704; *P* = 0.004) and DDFS (HR = 0.346; 95% CI 0.182--0.658; *P* = 0.001). In addition, Ezrin expression also remained the prognostic factor for DDFS (HR = 0.320; 95% CI 0.162--0.631; *P* = 0.001). Table 4Univariate and multivariate survival analyses of clinicopathologic factors, GPER and Ezrin expression.Univariate modelMultivariate model*P*\*OR95% CI for OR*P*\*\*HRβ95% CI for HRAny event Age0.8360.9970.974--1.022 Site (left vs right)0.5271.1820.704--1.986 Nuclear grade (G2 vs G3)0.0010.2030.083--0.5000.0010.240−1.4250.104--0.566 Tumor size0.0881.1460.980--1.340 LNM (no vs yes)\<0.0010.3690.216--0.6290.0720.621−0.4760.370--1.043 TNM (I/II vs III)\<0.0010.1870.101--0.3450.0020.436−0.8310.257--0.740 GPER (low vs high)\<0.0010.1730.096--0.313\<0.0010.393−0.9330.246--0.629 Ezrin (low vs high)\<0.0010.2740.156--0.4790.1410.697−0.3610.431--1.127Death Age0.4891.0090.983--1.036 Site (left vs right)0.6340.8710.493--1.538 Nuclear grade (G2 vs G3)0.0020.1530.046--0.5110.0070.201−1.6060.063--0.644 Tumor size0.0211.2151.030--1.4340.0231.1680.1561.022--1.336 LNM (no vs yes)\<0.0010.2180.118--0.4020.0640.533−0.6290.274--1.036 TNM (I/II vs III)\<0.0010.1190.063--0.2280.0020.359−1.0230.190--0.679 GPER (low vs high)\<0.0010.2590.142--0.4730.0250.528−0.6390.301--0.924 Ezrin (low vs high)\<0.0010.2660.147--0.4830.0730.595−0.5190.337--1.336Relapse event Age0.1970.9770.943--1.012 Site (left vs right)0.8081.0940.530--2.258 Nuclear grade (G2 vs G3)0.0490.2300.053--0.9940.0500.239−1.4330.057--1.001 Tumor size0.9501.0070.881--1.250 LNM (no vs yes)0.0050.3360.158--0.7160.2090.569−0.5640.236--1.372 TNM (I/II vs III)\<0.0010.2350.111--0.4980.0230.368−0.9980.156--0.871 GPER (low vs high)\<0.0010.2290.108--0.4850.0040.329−1.1130.153--0.704 Ezrin (low vs high)0.0190.4140.199--0.8630.7520.884−0.1240.410--1.904Distant event Age0.3010.9850.957--1.014 Site (left vs right)0.5290.8230.448--1.511 Nuclear grade (G2 vs G3)0.0100.2010.060--0.6760.0050.184−1.6950.056--0.602 Tumor size0.0751.1650.985--1.379 LNM (no vs yes)\<0.0010.3100.165--0.5850.0700.525−0.6440.262--1.053 TNM (I/II vs III)\<0.0010.1740.090--0.3340.0220.449−0.8010.227--0.889 GPER (low vs high)\<0.0010.1240.063--0.2420.0010.346−1.0610.182--0.658 Ezrin (low vs high)\<0.0010.1080.054--0.2140.0010.320−1.1390.162--0.631[^7][^8]

Discussion
==========

In our study, most cases presented with higher nuclear grades and worse TNM staging, which is characteristic of TNBC, together with a high degree of malignancy and rapid progression ([@bib23]). Large-scale clinical studies have found that TNBC has a higher risk of recurrence and metastasis, and a worse prognosis in young women than in post-menopausal patients ([@bib4]). Similar to the literature reported ([@bib4], [@bib24]), most of our patients are pre-menopausal women.

To the best our knowledge, until now, the clinical relevance of GPER expression in TNBC remains controversial. Some studies suggest that GPER expression is not associated with or inhibits the progression of TNBC ([@bib18], [@bib25]). We suspected this phenomenon may be related to the non-specific activity of the GPER-specific agonist G-1 ([@bib26]). Most studies found that GPER is prevalent in TNBC and associated with young age, and possibly with prognosis ([@bib17], [@bib27]). Our data also found GPER was mainly located in cancer nests and was significantly correlated with patients' TNM staging and survival outcomes: evidence which links the expression of GPER with TNBC clinical status.

When we focus on the patient's long-term survival, the data showed that the high expression of GPER correlated with high risk of death, local relapse and distant metastasis in TNBC. Further, we noted that GPER expression appears to be lower in younger TNBC patients with better prognosis. Therefore, we divided all patients into pre-menopausal and post-menopausal groups, and then separately studied the effect of GPER expression on outcome. According to the Kaplan--Meier analyses, it is highly likely that the role of GPER in predicting the prognosis of TNBC was mediated by estrogen. The mechanism may be related to an estrogen-activated GPER downstream cascade reaction, which promotes tumor cell proliferation, migration and invasion ([@bib7], [@bib27], [@bib28]).

However, Ezrin belongs to the actin-binding protein family and participates in cell behavior by modulating cytoskeleton rearrangement to promote the formation of membrane protrusions, such as filopodia, lamellipodia ([@bib29]). Ezrin could be phosphorylated more after 17β-estradiol activates GPER in ER(−) breast cancer cells, such as SK-BR-3 and MDA-MB-231, as previously described ([@bib15]). In this study, the positive relationship and similar prognostic role between GPER and Ezrin was identified. We hypothesize that for those TNBC women patients who are younger and have a higher GPER expression, high levels of estrogen in the body may promote tumorigenesis by activating signaling pathways downstream of GPER including Ezrin phosphorylation. By conducting a comprehensive analysis of the odds ratio of various clinical factors in the multivariate model, we found that only the DDFS survival rate is affected by both GPER and Ezrin. Although the reason of insufficient sample size can't be excluded, it also provides evidence for GPER to play a role in distant metastasis events.

In conclusion, we propose high GPER expression is a poor maker for young TNBC patients. GPER also might provide a new pathway for the prevention and treatment of all types of breast cancer, especially in those ER(+) breast cancer patients who have had a relapse or a drug-resistant event. Further studies on every molecular type of breast cancer could better characterize patients according to the expression of GPER.
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